Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O3OI
|
||||
| Former ID |
DIB004165
|
||||
| Drug Name |
AVL-3288
|
||||
| Indication | Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10:F01-F07, F04, F05, R41.3] | Phase 1 | [1] | ||
| Company |
Anvyl pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Neuronal acetylcholine receptor protein, alpha-7 chain | Target Info | Modulator | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Cholinergic synapse | |||||
| Nicotine addiction | |||||
| Chemical carcinogenesis | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Nicotinic acetylcholine receptor signaling pathway | |||||
| Reactome | Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | ||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01851603) Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects. U.S. National Institutes of Health. | ||||
| REF 2 | Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats. PLoS One. 2011;6(11):e27014. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.